$CRBP ANALYSIS – JUNE 1 2016

/ / FaisamTrader Blog, Stock Analysis

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company,

focuses on the development and commercialization of novel therapeutics to treat

inflammatory and fibrotic diseases. Its lead product candidate includes Resunab, a

novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the

treatment of cystic fibrosis, systemic sclerosis, and skin-predominant dermatomyositis

diseases. The company is based in Norwood, Massachusetts.

 

As of June 1 2016, CRBP looks to be bullish, for a 2 to 3 week hold. A purchase at a

price between $3.25 and $3.45 is safe and could bring you returns between 10% and

15% in the next 30 days. Be sure you place a stop loss at 5% below you buy price, and

don’t be greedy, a consistent 10% to 15% per month can help dealing with losses and

sometimes help bring in more profits.

 

Also please keep in mind we are not offer trading advice, we are just sharing an idea.

For real stock trading advice you should contact a professional financial advisor.

faq-bot-banner2

You must be logged in to post a comment.